Ceresil Canon, 125 mg/ml 4 ml 5 pcs
€1.00
Out of stock
(E-mail when Stock is available)
Pharmacodynamics
Citicoline is a natural endogenous compound, which is an intermediate metabolite in the synthesis of phosphatidylcholine, one of the main structural components of the cell membrane. Citicoline, being a precursor of the key ultrastructural components of the cell membrane (mainly phospholipids), has a broad spectrum of action – it helps restore damaged cell membranes, inhibits phospholipases, prevents the excessive formation of free radicals and prevents cell death by interfering with apoptosis mechanisms.
In the acute period of stroke citicoline reduces the amount of brain tissue damage, improves cholinergic transmission. In craniocerebral trauma reduces the duration of post-traumatic coma and severity of neurological symptoms, and also reduces the duration of the recovery period. In chronic cerebral hypoxia citicoline is effective in treating cognitive disorders such as memory impairment, lack of initiative, difficulties in daily activities and self-care. Increases the level of attention and consciousness, and reduces the manifestation of amnesia.
Citicoline is effective in the treatment of sensory and motor neurological disorders of degenerative and vascular etiology.
Pharmacokinetics
absorption
Citicoline is well absorbed when taken orally. Absorption after oral administration is almost complete and bioavailability is approximately the same as after intravenous administration.
Distribution
Citicoline is largely distributed in brain structures, with rapid incorporation of choline fractions into structural phospholipids and citidine fractions into citidine nucleotides and nucleic acids.
Citicoline penetrates the brain and is actively incorporated into cellular, cytoplasmic and mitochondrial membranes, forming part of the structural phospholipid fractions.
Metabolism
The drug is metabolized in the intestine and in the liver to form choline and cytidine. After ingestion, the plasma concentration of choline increases significantly.
Excretion
Only 15% of the administered dose of citicoline is excreted from the human body: less than 3% – by the kidneys and through the intestines and about 12% – with exhaled CO2.
Two phases can be distinguished in the excretion of citicoline with urine: the first phase lasting about 36 hours, during which the excretion rate decreases rapidly, and the second phase, during which the excretion rate decreases much slower. The same is observed in exhaled CC2 – the excretion rate decreases rapidly after about 15 hours and then decreases at a much slower rate.
Indications
- Acute period of ischemic stroke (as part of complex therapy).
- Cerebral trauma (CTS), acute (as part of complex therapy) and recovery period.
- Cognitive and behavioral disorders in degenerative and vascular diseases of the brain.
Active ingredient
Citicoline
Composition
1 ml of solution contains:
How to take, the dosage
Ceresil® Canon oral solution is administered orally. Before use the drug may be diluted in a small amount of water (100-120 ml or ½ cup).
Take during meals or between meals.
Recommended dosage regimen
Acute period of ischemic stroke and craniocerebral injury (CCI): 1000 mg (10 ml) every 12 h from the first day after diagnosis, treatment duration at least 6 weeks.
Recovery period of ischemic and hemorrhagic strokes, recovery period of CHT, cognitive and behavioral disorders in degenerative and vascular diseases of the brain: 500-2000 mg daily (5-10 ml 1-2 times daily). Dosage and duration of treatment depending on the severity of symptoms.
Interaction
Citicoline enhances the effects of levodopa.
Should not be used simultaneously with drugs containing meclofenoxate.
Special Instructions
Small amounts of crystals may form in the cold due to temporary partial crystallization of the preservative. Upon further storage under recommended conditions the crystals dissolve within several months. Presence of crystals does not affect the quality of the drug.
Effect on the ability to drive vehicles and mechanisms
During the treatment, caution should be exercised while performing potentially hazardous activities requiring particular attention and quick reactions (driving a car and other vehicles, working with moving machinery, work of dispatcher and operator, etc.).
Contraindications
- High sensitivity to any of the ingredients of the preparation
- Expecially marked vagotonia (predominance of the tone of the parasympathetic part of the autonomic nervous system);
- In the absence of sufficient clinical data, it is not recommended for use in children under 18 years.
.
Side effects
Frequency of side effects
Very rare (< 1/10000) (including individual cases): Allergic reactions (rash, skin itching, anaphylactic shock), headache, dizziness, fever, tremor, nausea, vomiting, diarrhea, hallucinations, edema, shortness of breath, insomnia, agitation, decreased appetite, numbness in paralyzed limbs, changes in liver enzyme activity.
In some cases, Ceresil® Canon may stimulate the parasympathetic system and also have a transient change in blood pressure.
If any of the side effects listed in the instructions are aggravated, or any other side effects not listed in the instructions have been noticed, the physician should be informed.
Overdose
Given the low toxicity of the drug, no cases of overdose have been described, even in the case of exceeding the therapeutic doses.
Similarities
Ceraxon, Recognan, Enzetron, Noocil oral solution 100 mg/ml 10 ml vials, 10 pcs, Ceremexin
Weight | 0.053 kg |
---|---|
Shelf life | 2 years. |
Conditions of storage | At a temperature not exceeding 25 ° C in the manufacturer's package. Keep out of reach of children. |
Manufacturer | Armavirskaya Biofabrika FKP, Russia |
Medication form | solution |
Brand | Armavirskaya Biofabrika FKP |
Related products
Buy Ceresil Canon, 125 mg/ml 4 ml 5 pcs with delivery to USA, UK, Europe and over 120 other countries.